The AIDS pandemic continues to spread unchecked in many parts of the world, with greater
than 34 million individuals currently infected with human immunodeficiency virus (HIV) …

Distinct from HIV-1 and often neglected in the global campaign to end the AIDS epidemic,
HIV-2 presents unique and underappreciated challenges in diagnosis, clinical care …

Human immunodeficiency virus type-2 (HIV-2) is a close relative of the prototype acquired
immunodeficiency syndrome (AIDS) virus, HIV-1. HIV-2 is biologically similar to HIV-1, but …

The causal relationships among CD4 cell depletion, HIV replication, and immune activation
are not well understood. HIV-2 infection,“nature's experiment” with inherently attenuated HIV …

A crucial requirement in the rational design of a prophylactic vaccine against the hu-uman
immunodeficiency virus (HIV) is to establish whether or not protective immunity can occur …

From a prospective cohort study of 1948 initially human immunodeficiency virus (HIV)
uninfected female commercial sex workers followed between 1985 and 1999 in Dakar …

The virulence properties of human immunodeficiency virus type 2 (HIV-2) are known to vary
significantly and to range from relative attenuation in certain individuals to high-level …

Objective: To measure the frequency and associated factors of cervicovaginal HIV shedding
and to determine the impact of sexually transmitted disease (STD) treatment on HIV …

Human immunodeficiency virus type 2 (HIV-2) is less pathogenic than HIV type 1 (HIV-1),
but the mechanisms underlying this difference have not been defined. We developed an …

Although human immunodeficiency virus type 1 (HIV-1) and HIV-2 share modes of
transmission, their epidemiologic characteristics differ and international spread of HIV-2 has …